| abstract |
Compounds that inhibit the binding of dengue virus nonstructural protein NS1 to complement regulatory protein clusterin, or that inhibit complement activation by NS1, can be used for treating dengue virus infection, dengue hemorrhagic fever, and dengue shock syndrome. Such compounds can be identified utilizing methods that measure inhibition of NS1/Clu binding, and/or inhibition of complement activation. |